Design, Synthesis and Evaluation of substituted Chromones as Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease.
Alzheimer's & Dementia · 2023-12 · 19 (S21)
DOI: 10.1002/alz.076869 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 25.12.2023. Verfasst von Naveen Kumar und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Background
Acetylcholinesterase (AChE) is one of the frontline targets involved in the progression of Alzheimer’s disease. AChE inhibitors are prescribed as the few drug therapies that have been proven clinically useful in the treatment of Alzheimer’s disease[1, 2]. AChE is involved in the termination of impulse transmission by rapid hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways[3]. The enzyme inactivation induced by various inhibitors, leads to acetylcholine accumulation, hyperstimulation of nicotine and muscarinic receptor and disrupted neurotransmission.
Method
A series of chromone derivatives were virtually screened, synthesised and biologically evaluated as acetylcholinesterase inhibitors. All the compounds were characterised by 1 H‐NMR, 13 C‐NMR and mass spectrometry.
Result
The in‐vitro evaluation of the compounds against hAChE enzyme showed promising inhibition varying in lower micromolar range. In the synthesized series, NSS‐17 is found to be the most potent AChE inhibitors (IC 50 = 1.59± 0.02 μM). In molecular docking studies, compound NSS‐17 showed similar interaction to AChE (1EVE) as shown by reference compound donepezil.
Conclusion
Thus, NSS‐17 can be used as promising lead for the development of more potent AChE inhibitors by further biological assays and in‐vivo studies. References [1] B. Kumar, A.R. Dwivedi, B. Sarkar, S.K. Gupta, S. Krishnamurthy, A.K. Mantha, J. Parkash, V. Kumar, 4,6‐Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer’s Disease, ACS Chemical Neuroscience 10(1) (2019) 252‐265. [2] B. Kumar, V. Kumar, V. Prashar, S. Saini, A.R. Dwivedi, B. Bajaj, D. Mehta, J. Parkash, V. Kumar, Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase, European Journal of Medicinal Chemistry 177 (2019) 221‐234. [3] B. Kumar, Sheetal, A.K. Mantha, V. Kumar, Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders, RSC Advances 6(48) (2016) 42660‐42683.
Zitieren
APA
Kumar, N., Kumar, V., Kumar, V., Kailash, & Kumar, V. (2023). Design, Synthesis and Evaluation of substituted Chromones as Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease. Alzheimer's & Dementia, 19(S21). https://doi.org/10.1002/alz.076869
Vancouver
Kumar N, Kumar V, Kumar V, Kailash, Kumar V. Design, Synthesis and Evaluation of substituted Chromones as Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease. Alzheimer's & Dementia. 2023;19(S21). doi:10.1002/alz.076869
BibTeX
@article{Kumar2023,
author = {Kumar, Naveen and Kumar, Vijay and Kumar, Vinay and Kailash and Kumar, Vinod},
title = {Design, Synthesis and Evaluation of substituted Chromones as Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {S21},
doi = {10.1002/alz.076869}
}
EUVIMED